AntiInfective Agents Global Market Outlook 20172023 [Report Updated: 01122017] Prices from USD $4150
According to Stratistics MRC,the Global AntiInfective Agents Market is accounted for $86.7 billion in 2016 and expected to grow at a CAGR of 3.8% to reach $113.16 billion by 2023. Rising incidences of infectious diseases such as HIV, H1N1, and Ebola virus, awareness amongst the patients, commercialization of pipeline products, Govt collaborating with pharmaceutical companies for the development of new agents, development of new multidrug resistance against microorganisms are boosting the market growth. Treatment rates for communicable diseases in developing countries and treatment of Community Acquired Bacterial Pneumonia CABP are expected to impart the market growth. Growing resistance of infection to the drug therapies, high price of drugs, competition between generic manufacturers and perilous reimbursement policies will impede market growth.
Based on Product, most of the Antibacterial agents are in pipeline for the modifications of existing antibiotic classes. More innovative products are required against pathogens with no cross or coresistance to existing classes. Many of the products in the clinical pipeline are already funded by research grants from public and philanthropic institutions.For instance, Delafloxacin was approved by the US Food and Drug Administration on 21 June 2017.
North America commanded the antiinfective agents market and is followed by Europe. Asia Pacific is the fastest growing market due to improvements in healthcare infrastructure, demand for drugs and ongoing government initiatives for various control programs.
Some of the key players in Global AntiInfective Agents market are Pfizer Ltd, Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd., AstraZeneca Plc, Boehringer Ingelheim, BristolMyers Squibb Co, Abbott Laboratories, Bayer Healthcare AG, Cipla Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Merck Co., Inc, Novartis AG, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Panacea Biotech Ltd and Claris Life Sciences Ltd.
Products Covered:
Antifungal agents
o Azoles
o Polyenes
o Allylamines
o Macrolides derivatives
o Cresemba
o Echinocandins
Antiviral agents
o Nonstructural protein 5A NS5A inhibitors
o Nonnucleoside reverse transcriptase inhibitors NNRTIs
o Protease Inhibitors
o Transcriptase Inhibitors
o Neuraminidase inhibitors
o Integrase strand transfer inhibitor
o Chemokine receptor antagonist
o DNA Polymerase Inhibitors
o Nucleoside Analogs
Antituberculosis agents
o Nicotinic acid derivatives
o Rifamycin derivatives
o Streptomyces derivatives
o Aminosalicylates
o Diarylquinolines
o Hydrazide derivatives
Antitreponemal agents
Vaccines
o DNA Recombinant vector Vaccines
o Toxoid vaccines
o Live/attenuated Vaccines
o Inactivated Vaccines
Antibacterial agents
o Clindamycin
o Sulfonamides
o Tetracyclines
o Vancomycin
o Cephalosporins
o Carbapenems
o Fluoroquinolones
o Penicillins
o Macrolides
Regions Covered:
North America
o US
o Canada
o Mexico
Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
South America
o Argentina
o Brazil
o Chile
o Rest of South America
Middle East Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East Africa
What our report offers:
Market share assessments for the regional and country level segments
Market share analysis of the top industry players
Strategic recommendations for the new entrants
Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
Market Trends Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements
Original Article: AntiInfective Agents Global Market Outlook 20172023 [Report Updated: 01122017] Prices from USD $4150
